Tests a lung-sparing radiation plan in people with lung cancer
Tests a planning method to spare healthy lung during radiation for lung cancer.
Plain-language title generated from the registry record
Registry title: Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy
Key facts
- Where
- Liverpool, AustraliaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage 3 non-small cell lung cancer who will have full-dose radiation therapy aimed at removing all of the cancer. It tests a planning method that spares the healthiest parts of the lungs.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Non-small cell lung cancer proven by tissue examination, stage 3 (IASLC 8th edition). Daily activity level (ECOG) 0-2. The standard radiation plan must show that at least 16% of lung volume (not counting the tumour) would get more than 20 Gy.
- Earlier treatment
- Must be planned for radiation therapy aimed at removing all of the disease (60 Gy in 30 treatments or 55 Gy in 20 treatments), with or without chemotherapy at the same time and PD1/PD-L1 inhibitors afterwards. Cannot have had earlier chest radiation, chemotherapy for this cancer, or surgery for this cancer within a year.
- Biomarker or test result
- A whole body PET scan and lung function tests within 8 weeks of registration. A quality of life score (FACT-L TOI) of 5 or more.
Main reasons for not taking part
- Serious other medical conditions that make radiation aimed at removing the cancer unsafe
- Current or past interstitial lung disease
- Lung cancer in the past 5 years
- Pregnant or breastfeeding women
- Cannot attend all radiation sessions or follow-up visits
Read by machine on 12 November 2026.
Where in Australia
- SWSLHD - Liverpool, Campbelltown and Bankstown-Lidcombe HospitalsLiverpool, AustraliaContact: Clinical Trial CoordinatorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Sydney
- Trial code
- NCT06127654
- Record updated
- 19 May 2026
- Original description
This research project is testing a new treatment planning method for patients with lung cancer who will be treated with radiation therapy. This new method is called Computed Tomography (CT) ventilation imaging. It aims to help protect the healthiest parts of patient's lungs from being injured by the radiation therapy. The investigators will determine whether healthy lung sparing can improve the quality of life in these patients.Read full original descriptionShow less
VITaL: A Randomised Controlled Trial Investigating Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy
This research project is testing a new treatment planning method for patients with lung cancer who will be treated with radiation therapy. This new method is called Computed Tomography (CT) ventilation imaging. It aims to help protect the healthiest parts of patient's lungs from being injured by the radiation therapy. The investigators will determine whether healthy lung sparing can improve the quality of life in these patients.
Inclusion: Aged 18 years or older; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Histologically proven non-small cell lung cancer; Stage 3 as determined using the IASLC (International Association for the Study of Lung Cancer) 8th edition lung cancer staging guidelines; To be treated with curative intent external beam radiotherapy (60 Gy in 30 treatments or 55 Gy in 20 treatments) +/- concurrent chemotherapy and adjuvant PD1/PD-L1 inhibitors; Whole body Positron Emission Tomography (PET) scan within 8 weeks of registration; Pulmonary function tests within 8 weeks of registration; Willingness to give written informed consent; Willingness to comply with the study procedures and visit requirements; Available for follow up for a minimum of 12 months and up to 3 years; Post-inclusion criteria includes the results of a Quality of Life (QoL) assessment and treatment plan assessment, neither of which are known prior to consent. The post-inclusion criteria for the VITaL trial are:; Functional Assessment of Cancer Therapy - Lung (FACT-L) Trial Outcome Index (TOI) score of ≥5, the clinically meaningful difference; The standard treatment plan shows that at least 16% of volume of the lungs (minus the Gross Tumour Volume (GTV)) will receive more than 20 Gy. This criterion is based on the difference in pneumonitis risk between patients receiving below (~8%) and above (~34%) this threshold; The QoL assessment is unlikely to eliminate any patients but is included for patients where no clinically meaningful difference will be possible. The treatment plan assessment may exclude 20% of otherwise eligible patients.
Exclusion: Serious medical comorbidities that may contraindicate curative radiotherapy; Inability to attend full course of radiotherapy or follow-up visits; Prior history of lung cancer within 5 years; Prior thoracic radiotherapy at any time; Prior surgery for this cancer within a year; Prior chemotherapy for this cancer; A current or former diagnosis of interstitial lung disease; Pregnant or lactating women.